| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dates (the fruit of Phoenix dactylifera) have been increasingly studied for their potential anticancer and cancer-preventive properties, mainly due to their rich phytochemical content and strong antioxidant activity. Dates contain a broad spectrum of bioactive compounds linked to cancer prevention: -Phenolic acids – e.g., ferulic acid, gallic acid, caffeic acid, and p-coumaric acid -Flavonoids – e.g., quercetin, luteolin, apigenin -Carotenoids – e.g., β-carotene, lutein -Tannins, saponins, and sterols -Dietary fiber and polysaccharides These compounds have antioxidant, anti-inflammatory, and antiproliferative effects. Date fiber and polyphenols foster beneficial gut bacteria (e.g., Bifidobacterium, Lactobacillus) that produce short-chain fatty acids (SCFAs), which protect the colon and may lower colon cancer risk. Date Fruit Extract — a non-standardized botanical extract prepared from the edible fruit pulp of Phoenix dactylifera L., including cultivars such as Ajwa, Medjool, Hallawi, Sukkari, and others. It is classified as a complex food-derived phytochemical mixture rather than a single defined drug or active pharmaceutical ingredient. The standard abbreviation is DFE. Principal constituents vary substantially with cultivar, ripeness, processing, and extraction solvent, but commonly include phenolic acids such as gallic, ferulic, caffeic, protocatechuic, and p-coumaric acids; flavonoids such as quercetin, luteolin, apigenin, catechin, and epicatechin derivatives; carotenoids; condensed tannins; polysaccharides; and dietary fiber. Date fruit, date seed, leaf, pollen, and nanoparticle preparations are compositionally distinct and should not be treated as interchangeable with fruit-pulp extract. Primary mechanisms (ranked):
Bioavailability / PK relevance: No clinically validated pharmacokinetic profile exists for DFE as a standardized anticancer agent. Its polyphenols undergo incomplete intestinal absorption, extensive phase-II conjugation, microbial metabolism, and rapid systemic clearance. Consequently, circulating concentrations of individual parent compounds are generally much lower than concentrations used for direct cancer-cell cytotoxicity. Local gastrointestinal exposure and microbial metabolites may be more biologically relevant than systemic exposure after ordinary date consumption. In-vitro vs systemic exposure relevance: Most antiproliferative studies use crude solvent fractions at tens to hundreds of micrograms per millilitre. These concentrations cannot be directly equated with plasma exposure after eating dates or taking an unstandardized extract. Extract-specific cytotoxic effects may reflect concentrated mixtures, solvent-selective enrichment, or interactions among multiple constituents. Common in-vitro exposures probably exceed achievable systemic concentrations from dietary intake. Clinical evidence status: Preclinical. Evidence consists primarily of cell-culture studies, limited animal experiments, compositional studies, and small human dietary studies evaluating metabolic, inflammatory, or gastrointestinal outcomes. No randomized controlled oncology trial has established DFE as a cancer treatment, adjunctive anticancer therapy, radiosensitizer, or chemotherapy sensitizer. Date fruit and date-derived extracts are not approved by Health Canada, the FDA, or the EMA as anticancer drugs. Safety and deployment: Whole dates are conventional foods and are generally well tolerated, but they contain substantial carbohydrate and sugar and may require portion control in people with impaired glycemic regulation. Extracts may differ markedly from the food in concentration, solvent residues, composition, and contaminant risk. Clinical interaction data with chemotherapy, anticoagulants, endocrine therapies, or targeted agents are inadequate. DFE should not be assumed to protect normal tissue selectively or improve anticancer treatment efficacy without direct combination studies. Date Fruit Extract Mechanistic Profile
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Caspases are a cysteine protease that speed up a chemical reaction via pointing their target substrates following an aspartic acid residue.1 They are grouped into apoptotic (caspase-2, 3, 6, 7, 8, 9 and 10) and inflammatory (caspase-1, 4, 5, 11 and 12) mediated caspases. Caspase-1 may have both tumorigenic or antitumorigenic effects on cancer development and progression, but it depends on the type of inflammasome, methodology, and cancer. Catalase is an enzyme found in nearly all living cells exposed to oxygen. Its primary role is to protect cells from oxidative damage by catalyzing the conversion of hydrogen peroxide (H₂O₂), a potentially damaging byproduct of metabolism, into water (H₂O) and oxygen (O₂). This detoxification process is crucial because excess H₂O₂ can lead to the formation of reactive oxygen species (ROS) that damage proteins, lipids, and DNA. Catalase and Cancer Oxidative Stress and Cancer: Cancer cells often experience increased levels of oxidative stress due to rapid proliferation and metabolic changes. This stress can lead to DNA damage, promoting tumorigenesis. Catalase helps mitigate oxidative stress, and its expression can influence the survival and proliferation of cancer cells. Expression Levels in Different Cancers: Overexpression: In some cancers, such as breast cancer and certain types of leukemia, catalase may be overexpressed. This overexpression can help cancer cells survive in oxidative environments, potentially leading to more aggressive tumor behavior. Downregulation: Conversely, in other cancers, such as colorectal cancer, reduced catalase expression has been observed. This downregulation can lead to increased oxidative stress, contributing to tumor progression and metastasis. Prognostic Implications: Survival Rates: Studies have shown that high levels of catalase expression can be associated with poor prognosis in certain cancers, as it may enable cancer cells to resist apoptosis (programmed cell death) induced by oxidative stress. Some types of cancer cells have been reported to exhibit lower catalase activity, possibly increasing their vulnerability to oxidative damage under certain conditions. This vulnerability has even been exploited in some therapeutic strategies (for example, approaches that generate excess H₂O₂ or other ROS specifically targeting cancer cells have been researched). |
| 6663- | DFE, | Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 6668- | DFE, | AgNPs, | Saponin-Derived Silver Nanoparticles from Phoenix dactylifera (Ajwa Dates) Exhibit Broad-Spectrum Bioactivities Combating Bacterial Infections |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:371 Target#:46 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid